ArticleInvestigational new drugs2020
Evaluation of absorption, distribution, metabolism, and excretion of [
Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Human Absorption, Metabolism, and Excretion (hAME) Mass Balance Studies in Patients With Cancer.Clinical and translational science · 2026Review
- Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.Future oncology (London, England) · 2026Review
- Bioanalytical assay for the quantification of rucaparib in rat plasma using UPLC-MS/MS: development, and validation for interaction with myricetin.Frontiers in pharmacology · 2025Article
- Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA-Seq and Bulk RNA-Seq: A Model Development and Validation Study.Cancer medicine · 2025Article
- Pharmacokinetics, Mass Balance and Metabolism of [European journal of drug metabolism and pharmacokinetics · 2023Article
- Article
- Study of the mass balance, biotransformation and safety of [Frontiers in pharmacology · 2023Article
- Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.Clinical pharmacokinetics · 2022Review
- Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.Clinical pharmacokinetics · 2022Review
- Imaging PARP with [European journal of nuclear medicine and molecular imaging · 2022Article
- A cyanide-catalyzed imino-Stetter reaction enables the concise total syntheses of rucaparib.RSC advances · 2022Article
- A Novel Classification Model for Lower-Grade Glioma Patients Based on Pyroptosis-Related Genes.Brain sciences · 2022Article
- Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.Cancer chemotherapy and pharmacology · 2022Article
- Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.Cancers · 2022Review
- Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.Cancer chemotherapy and pharmacology · 2021Article
- Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, is licensed for use in recurrent ovarian, fallopian tube, or primary peritoneal cancer. We characterized the absorption, distribution, metabolism, and elimination of rucaparib in 6 patients with advanced solid tumors following a single oral dose of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.